Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.17 USD
Change Today +0.02 / 0.63%
Volume 9.8K
CLRB On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

cellectar biosciences inc (CLRB) Snapshot

Open
$3.17
Previous Close
$3.15
Day High
$3.27
Day Low
$2.99
52 Week High
05/2/14 - $9.20
52 Week Low
10/20/14 - $1.76
Market Cap
24.0M
Average Volume 10 Days
16.1K
EPS TTM
$-2.53
Shares Outstanding
7.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELLECTAR BIOSCIENCES INC (CLRB)

Related News

No related news articles were found.

cellectar biosciences inc (CLRB) Related Businessweek News

No Related Businessweek News Found

cellectar biosciences inc (CLRB) Details

Cellectar Biosciences, Inc., a development stage biopharmaceutical company, develops compounds for the treatment and imaging of cancer. Its proprietary product candidates include I-124-CLR1404, a small-molecule, broad-spectrum, and cancer-targeting positron emission tomography (PET) imaging agent that is in Phase II clinical trial for glioblastoma, as well as in Phase I/II clinical trials for approximately 11 solid tumor indications; and CLR1502, a preclinical, cancer-targeted, and non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. The company also develops I-131-CLR1404, a small-molecule, broad-spectrum, and cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells, as well as is in Phase Ib dose-escalation trial for patients with advanced solid tumors; and CLR1404, a cancer-targeted chemotherapy. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.

cellectar biosciences inc (CLRB) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: --
Founder, Chief Scientific Officer and Directo...
Total Annual Compensation: $180.3K
Compensation as of Fiscal Year 2013.

cellectar biosciences inc (CLRB) Key Developments

Cellectar Biosciences, Inc. Reports Earnings Results for the Year Ended December 31, 2014

Cellectar Biosciences, Inc. reported earnings results for the year ended December 31, 2014. The company reported a net loss attributable to common stockholders for the year ended December 31, 2014 of approximately $8.1 million or $1.77 per share compared to a net loss attributable to common stockholders of approximately $10.8 million or $3.86 per share for the year ended December 31, 2013.

Cellectar Biosciences, Inc., Q4 2014 Earnings Call, Mar 24, 2015

Cellectar Biosciences, Inc., Q4 2014 Earnings Call, Mar 24, 2015

Cellectar Biosciences, Inc. Presents at 27th Annual ROTH Conference, Mar-10-2015 03:30 PM

Cellectar Biosciences, Inc. Presents at 27th Annual ROTH Conference, Mar-10-2015 03:30 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: Jamey P. Weichert, Founder, Chief Scientific Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLRB:US $3.17 USD +0.02

CLRB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLRB.
View Industry Companies
 

Industry Analysis

CLRB

Industry Average

Valuation CLRB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLECTAR BIOSCIENCES INC, please visit www.cellectar.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.